Strensiq and Claritin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Strensiq (asfotase alfa) and Claritin (loratadine). Common drug interactions include injection site reaction among females and blood alkaline phosphatase increased among males.

The phase IV clinical study analyzes what interactions people have when they take Strensiq and Claritin. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Strensiq?

Strensiq has active ingredients of asfotase alfa. eHealthMe is studying from 7,141 Strensiq users. Check the latest studies of Strensiq.

What is Claritin?

Claritin has active ingredients of loratadine. It is often used in allergies. eHealthMe is studying from 77,315 Claritin users. Check the latest studies of Claritin.

On Jul, 18, 2026

13 people who take Strensiq and Claritin together, and have interactions are studied.

Strensiq and Claritin drug interactions.

What are the common drug interactions of Strensiq and Claritin, by gender? *:

female:

Injection site reaction
Injection site swelling
Pruritus (severe itching of the skin)
Injection site pruritus (severe itching at injection site)
Injection site urticaria (rash of round, red welts on the skin at injection site)
Migraine (headache)
Rash macular (small, flat red spots)
Injection site discolouration
Injection site discomfort
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)

male:

Blood alkaline phosphatase increased
Blood phosphorus increased
Injection site atrophy (injection site wasting or decreasing in size of a body organ, tissue, or part)
Injection site bruising
Injection site mass

What are the common drug interactions of Strensiq and Claritin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Blood alkaline phosphatase increased
Blood phosphorus increased
Injection site atrophy (injection site wasting or decreasing in size of a body organ, tissue, or part)
Injection site bruising
Injection site mass

10-19:

n/a

20-29:

Nephrolithiasis (calculi in the kidneys)
Substance abuse

30-39:

n/a

40-49:

n/a

50-59:

Injection site erythema (redness at injection site)
Injection site pain
Hot flush (sudden feelings of heat)
Injection site reaction
Injection site swelling
Injection site warmth
Pruritus (severe itching of the skin)
Urticaria (rash of round, red welts on the skin that itch intensely)

60+:

n/a

What are the existing conditions these people have? *

Hypophosphatasia (metabolic bone disease): 10 people, 76.92%
Muscle Aches (muscle pain): 3 people, 23.08%
Insomnia (sleeplessness): 3 people, 23.08%
Hypersensitivity: 3 people, 23.08%
Constipation: 3 people, 23.08%
Chest Wall Abscess: 3 people, 23.08%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 3 people, 23.08%
Asthma: 3 people, 23.08%
Ankylosing Spondylitis (type of arthritis affecting the spine): 3 people, 23.08%
Acne (skin problems that cause pimples): 3 people, 23.08%

* Approximation only. Some reports may have incomplete information.

Do you take Strensiq and Claritin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously